DiaMedica Therapeutics Inc. (DMAC) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2025)

-$32.8M

Total Assets (FY2025)

$61.4M

Total Equity (FY2025)

$56.1M

Cash Flows from Operating Activities (FY2025)

-$29.1M

Source: DiaMedica Therapeutics Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.